Last reviewed · How we verify

Levobupivacaine PCA group

Osijek University Hospital · FDA-approved active Small molecule

Levobupivacaine PCA group is a Local anesthetic (amide) Small molecule drug developed by Osijek University Hospital. It is currently FDA-approved for Postoperative pain management via patient-controlled analgesia (PCA), Regional anesthesia and analgesia. Also known as: Postoperative continuous wound infiltration analgesia with local anesthetic, Chirocaine 0.5%.

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Postoperative pain management via patient-controlled analgesia (PCA), Regional anesthesia and analgesia.

At a glance

Generic nameLevobupivacaine PCA group
Also known asPostoperative continuous wound infiltration analgesia with local anesthetic, Chirocaine 0.5%
SponsorOsijek University Hospital
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting amide local anesthetic. It works by reversibly binding to and blocking voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and conduction of nerve impulses. When administered via patient-controlled analgesia (PCA), it provides regional anesthesia and postoperative pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levobupivacaine PCA group

What is Levobupivacaine PCA group?

Levobupivacaine PCA group is a Local anesthetic (amide) drug developed by Osijek University Hospital, indicated for Postoperative pain management via patient-controlled analgesia (PCA), Regional anesthesia and analgesia.

How does Levobupivacaine PCA group work?

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

What is Levobupivacaine PCA group used for?

Levobupivacaine PCA group is indicated for Postoperative pain management via patient-controlled analgesia (PCA), Regional anesthesia and analgesia.

Who makes Levobupivacaine PCA group?

Levobupivacaine PCA group is developed and marketed by Osijek University Hospital (see full Osijek University Hospital pipeline at /company/osijek-university-hospital).

Is Levobupivacaine PCA group also known as anything else?

Levobupivacaine PCA group is also known as Postoperative continuous wound infiltration analgesia with local anesthetic, Chirocaine 0.5%.

What drug class is Levobupivacaine PCA group in?

Levobupivacaine PCA group belongs to the Local anesthetic (amide) class. See all Local anesthetic (amide) drugs at /class/local-anesthetic-amide.

What development phase is Levobupivacaine PCA group in?

Levobupivacaine PCA group is FDA-approved (marketed).

What are the side effects of Levobupivacaine PCA group?

Common side effects of Levobupivacaine PCA group include Hypotension, Bradycardia, Nausea, Dizziness, Systemic toxicity (at high doses).

What does Levobupivacaine PCA group target?

Levobupivacaine PCA group targets Voltage-gated sodium channels and is a Local anesthetic (amide).

Related